Primary Care Diabetes
Volume 1, Issue 2 , Pages 69-74 , June 2007

Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: The ADDITION Netherlands study

  • Paul G.H. Janssen

      Affiliations

    • Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author at: Julius Center for Health Sciences and Primary Care, University Medical Center, PO Box 85060, 3508 AB Utrecht, The Netherlands. Tel.: +31 30 2538251; fax: +31 30 2539028.
    • ,
  • Kees J. Gorter

      Affiliations

    • Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
    • ,
  • Ronald P. Stolk

      Affiliations

    • Department of Epidemiology, University Medical Center, Groningen, The Netherlands
    • ,
  • Guy E.H.M. Rutten

      Affiliations

    • Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands

Received 4 December 2006 ,Revised 17 February 2007 ,Accepted 19 February 2007.

References 

  1. Rajala U, Laakso M, Qiao Q, Keinanen-Kiukaanniemi S. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance and normal glucose tolerance. Diab. Care. 1998;21:1664–1669
  2. Spijkerman AMW, Henry RMA, Dekker JM, et al. The prevalence of macrovascular disease at the time of diagnosis of type 2 diabetes among diabetic patients detected by targeted screening and newly diagnosed diabetic patients in general practice: The Hoorn Screening Study. J. Intern. Med. 2004;256:429–436
  3. Spijkerman AM, Adriaanse MC, Dekker JM, et al. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diab. Care. 2002;25:1784–1789
  4. De Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285:2109–2113
  5. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diab. Med. 2002;19:708–723
  6. Carnevale Schianca GP, Rossi A, Sainaghi PP, et al. The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diab. Care. 2003;26:1333–1337
  7. DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diab. Care. 2003;26:61–69
  8. DECODA Study Group. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diab. Care. 2003;26:1770–1780
  9. Smith NL, Barzilay JI, Shaffer D, et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch. Intern. Med. 2002;162:209–216
  10. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia. 2003;46(Suppl. 1):M17–M21
  11. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diab. Care. 1999;22:920–924
  12. Hanefeld M, Temelkova-Kurktschiev T, Schaper F, et al. Impaired fasting glucose is not a risk factor for atherosclerosis. Diab. Med. 1999;16:212–218
  13. Blake DR, Meigs JB, Muller DC, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes. 2004;53:2095–2100
  14. Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diab. Care. 1999;22:45–49
  15. Novoa FJ, Boronat M, Saavedra P, et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diab. Care. 2005;28:2388–2393
  16. P.G.H. Janssen, K.J. Gorter, R.P. Stolk, G.E.H.M. Rutten, Population-based screening for type 2 diabetes in The Netherlands is not efficient. The ADDITION Netherlands study, submitted for publication.
  17. Rasmussen SS, Glümer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark. Diabetologia. 2007;50:293–297
  18. World Health Organization, Definition, diagnosis and classification of diabetes mellitus and its complications, Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus, World Health Organization, Geneva, 1999.
  19. Rutten GEHM, Verhoeven S, Heine RJ, et al. Dutch College of General Practitioners’ guidelines on type 2 diabetes mellitus. Huisarts Wet. 1999;42:67–84(in Dutch)
  20. Heldgaard PE, de Fine Olivarius N, Hindsberger C, Henriksen JE. Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease. Diabet. Med. 2004;21:363–370
  21. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diab. Care. 2003;26:3160–3167
  22. Forouhi NG, et al. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia. 2006;49:822–827
  23. Wen CP, Cheng TY, Tsai SP, et al. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diab. Care. 2005;28:2756–2761
  24. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch. Intern. Med. 2001;161:1581–1586
  25. Hu G, Tuomilehto J, Silventoinen K, et al. The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47212 middle-aged Finnish men and women. Int. J. Obes. 2005;29:894–902
  26. Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 2002;162:1867–1872
  27. Yan LL, Daviglus ML, Liu K, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA. 2006;295:190–198
  28. Spijkerman AM, Griffin SJ, Dekker JM, Nijpels G, Wareham NJ. What is the risk of mortality for people who are screen positive in a diabetes screening programme but who do not have diabetes on biochemical testing? Diabetes screening programmes from a public health perspective. J. Med. Screen. 2002;9:187–190
  29. P.G.H. Janssen, K.J. Gorter, R.P. Stolk, M. Akarsubasi, G.E.H.M. Rutten, Three years follow-up of screen detected diabetic and non-diabetic subjects: who is better off? The ADDITION Netherlands study, submitted for publication.

PII: S1751-9918(07)00032-0

doi: 10.1016/j.pcd.2007.02.001

Primary Care Diabetes
Volume 1, Issue 2 , Pages 69-74 , June 2007

Article Tools

* Image Usage & Resolution